Myriad Commercially Launches Precise MRD with Select Community Oncologists
MWN-AI** Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced the limited launch of its innovative Precise MRD™ (molecular residual disease) test, targeting breast cancer patients within select community oncology practices. This test, which employs advanced technology to detect circulating tumor DNA (ctDNA) at extraordinarily low levels, aims to provide timely insights into cancer treatment effectiveness, enabling physicians to make more informed decisions regarding patient care.
Brian Donnelly, Chief Commercial Officer of Myriad Genetics, emphasized the significance of this milestone, asserting that the Precise MRD test represents a vital advancement for both patients and clinicians. Designed to facilitate ongoing monitoring during treatment, the tumor-informed assay employs whole-genome sequencing to create personalized profiles for each patient, offering ultra-sensitive detection capabilities down to one part per million.
Medical professionals, such as Dr. Derrick S. Haslem, have lauded the test as a transformative tool in oncology, allowing for the identification of residual cancer cells post-treatment that may evade detection through traditional imaging methods. The initial phase of the test's rollout will involve community oncologists without limitations on patient participation, and a broader national launch is planned for later in the year.
The Precise MRD test not only assists in determining the necessity for adjuvant therapy but also monitors disease progression, providing actionable data regarding patient treatment responses. Clinicians will receive straightforward reports detailing ctDNA detection and concentration over time, enhancing their capacity to tailor therapies to individual needs.
Myriad Genetics, a leader in molecular diagnostics, underscores its commitment to precision medicine, aiming to improve patient outcomes while also striving to reduce healthcare costs. Further information can be found on their website.
MWN-AI** Analysis
Myriad Genetics, Inc. (NASDAQ: MYGN) has recently launched its innovative Precise MRD™ test for breast cancer, marking a significant advancement in molecular diagnostics. This initiative is a critical milestone for investors to observe, as it indicates Myriad’s commitment to enhancing its product offerings in the rapidly evolving field of precision medicine.
The Precise MRD test, designed to detect circulating tumor DNA (ctDNA) at remarkably low levels, is particularly promising for its potential to allow oncologists to make more informed treatment decisions. The ability to monitor patients longitudinally, coupled with whole-genome sequencing technology, positions Myriad well in a competitive market. The initial selective rollout suggests a measured approach, allowing for the accumulation of real-world data while minimizing operational risks.
From a market perspective, the implications of this launch are multifaceted. Firstly, the collaboration with community oncologists provides a direct line into patient care environments, enhancing the likelihood of adoption as trust in the product builds. Furthermore, as Myriad prepares for a broader launch across the U.S. later this year, investors should watch for indications of market uptake, measured by clinician feedback and patient outcomes.
Financially, the precision oncology market is expected to expand significantly, with increasing demand for personalized healthcare solutions. This trend could lead to increased revenues for Myriad, particularly if the Precise MRD test shows efficacy and reliability in clinical settings. Investors should also monitor the company’s communications regarding adoption rates and future profits stemming from the test.
In conclusion, Myriad's new diagnostic test represents an exciting opportunity for the company and investors. A close watch on its market performance and uptake will be crucial in evaluating potential long-term growth and profitability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer.
“The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low levels, the Precise MRD test will enable earlier insight and more informed treatment decisions,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. “This launch demonstrates the new Myriad’s ability to execute with discipline and deliver innovative diagnostics on a defined commercial timeline.”
The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a personalized assay for each patient, Precise MRD enables ultrasensitive detection of ctDNA down to one part per million.
"As a medical oncologist, I am excited about the advancements being made in our ability to detect, treat, and monitor cancer,” said Derrick S. Haslem, MD, ACMO of Specialty Care at Intermountain Health in Desert Region. “Precise MRD testing has emerged as a powerful tool in modern oncology, enabling physicians to detect cancer cells that persist after treatment but remain invisible to conventional imaging and microscopic examination.”
In this initial launch, the test will be available to community oncologists whose patients have been diagnosed with breast cancer. The initial roll-out will involve selected oncology practices, with no limit on the number of participating patients. Myriad is planning a broader commercial launch of the Precise MRD test across the U.S. later this year for patients with breast cancer.
“Precise MRD gives us greater visibility into whether treatment is working, which is especially important for a rural practice. A lot of my patients travel many miles to come to my office, so conducting multiple screening tests, like imaging, to determine if their cancer has spread can be physically difficult,” said Sucharu Prakash, MD, Director of Quality Services for Texas Oncology and Past President of Texas Society of Clinical Oncology. “The Precise MRD test represents an important component in determining – on a personalized basis – what and how many cancer treatments we should prescribe or order.”
About Precise MRD
The Precise MRD test provides molecular insights across the cancer care continuum. After diagnosis, the test can help clinicians determine if adjuvant treatment is needed, or if cancer has recurred. Should cancer metastasize in a patient, Precise MRD can provide molecular insights showing whether treatment is working or if a patient’s ctDNA is increasing.
For baseline tests, a personalized panel is developed based on a whole-genome sequencing profile of tumor tissue, and then the panel is used to measure the ctDNA level from an initial blood draw. For ongoing monitoring, the panel measures ctDNA levels from samples collected with a frequency based on where patients are in the treatment process.
Clinicians will receive an easy-to-read report that shows whether ctDNA was detected or not. If ctDNA is detected, the concentration of ctDNA is reported, which allows clinicians to see historical results of the patient’s ctDNA concentration over time.
Learn more at myriad.com/oncology/precise-mrd-test/.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the Precise MRD test will enable earlier insight and more informed treatment decisions and the Company is planning a broader commercial launch of the Precise MRD test across the U.S. later this year for patients with breast cancer. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ**
How does the launch of the Precise MRD™ test by Myriad Genetics Inc. MYGN fit into the company's long-term strategy for growth in the oncology diagnostics market?
What potential impact will the Precise MRD™ test have on the competitive landscape for molecular testing companies, including Myriad Genetics Inc. MYGN?
How does Myriad Genetics Inc. MYGN plan to leverage the initial success of the Precise MRD™ test to garner wider adoption among oncologists across the U.S.?
What are the expected financial implications for Myriad Genetics Inc. MYGN following the broader commercial launch of the Precise MRD™ test later this year?
**MWN-AI FAQ is based on asking OpenAI questions about Myriad Genetics Inc. (NASDAQ: MYGN).
NASDAQ: MYGN
MYGN Trading
-0.97% G/L:
$5.13 Last:
678,039 Volume:
$4.96 Open:
